Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...

Tvardi Therapeutics Inc. research and ratings by Barron's. View TVRD revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Catalyst Pharmaceuticals Inc. research and ratings by Barron's. View CPRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

The company offers a quarterly dividend of $0.43 per share for a dividend yield of 7.72%, as of May 9. Overall, Pfizer Inc. (NYSE:PFE) ranks first on our list of the best high yield dividend stocks.

Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks for companies returning cash to ...

This steep decline, driven by waning COVID-19 product sales and tariff uncertainties, has sparked debate about whether PFE’s current valuation, bolstered by a 7.5% dividend yield and a forward P ...

Pfizer’s fundamentals paint a mixed picture: a PE ratio of 16.15 is reasonable, the dividend yield of 7.55% is downright generous, and the payout ratio at 124.64% is ambitious—perhaps a little too ...